Professor, Medicine, University of Illinois College of Medicine
Oncology
Dr. David J. Peace, MD
|
|
Give Review
David J. Peace, MD works in the field of Oncology. He graduated from University of Pittsburgh School of Medicine. David Peace is also a published physician. He has 52 publication published. The most recent publication is: High-dose chemotherapy combined with escalating doses of cyclosporin A and an autologous bone marrow transplant for the treatment of drug-resistant solid tumors: a pha... Doctor David J. Peace, MD accepts Medicare payments and is listed with Medicare.gov.
Publications
- Nonmyeloablative Stem Cell Transplantation with Alemtuzumab/Low-Dose Irradiation to Cure and Improve the Quality of Life of Adults with Sickle Cell Disease.
- FHL2 regulates hematopoietic stem Cell functions under stress conditions.
- Combination of linear accelerator-based intensity-modulated total marrow irradiation and myeloablative fludarabine/busulfan: a phase I study.
- Improved outcomes with novel agents and auto-SCT for multiple myeloma in African-American patients.
- An introduction to foundation and industry-sponsored research: practical and ethical considerations.
- Distinct cytokine patterns exist in peripheral blood mononuclear cell cultures of patients with prostate Cancer.
- 25-OH-vitamin D deficiency and Cellular alloimmunity as measured by panel of reactive T Cell testing in dialysis patients.
- EBV positivity in primary cutaneous large B-Cell lymphoma with immunophenotypic features of leg type: an isolated incident or something more significant?
- High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian Cancer: a multivariate analysis of survival for 100 consecutively treated patients.
- Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3gamma1(Ala-Ala) in the treatment of Acute renal allograft rejection.
- IL-4-induced lymphokine-activated killer Cells. Lytic activity is mediated by phenotypically distinct natural killer-like and T Cell-like large granular lymphocytes.
- T Cell recognition of transforming proteins encoded by mutated ras proto-oncogenes.
- Exercise in patients receiving hematopoietic stem Cell transplantation: lessons learned and results from a feasibility study.
- Biologic activity of interleukin 1 (IL-1) alpha in patients with refractory malignancies.
- Primary pancreatic sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman Disease): an unusual extranodal manifestation clinically simulating malignancy.
- Antigen-specific cultured T Cells can mediate tumor therapy and provide long-term immunologic memory in vivo.
- Il-4 is an endogenous T Cell growth factor during the immune response to a syngeneic retrovirus-induced tumor.
- Aggressive primary splenic CD5 positive/Cyclin D1 negative B-Cell lymphoma in a patient with chronic hepatitis B virus infection.
- A phase II trial of high-dose mitoxantrone, carboplatin, and cyclophosphamide with autologous bone marrow rescue for recurrent epithelial ovarian carcinoma: Analysis o...
- High-dose chemotherapy combined with escalating doses of cyclosporin A and an autologous bone marrow transplant for the treatment of drug-resistant solid tumors: a pha...
- The use of blood conservation methods in addition to erythropoietin allows myeloablative allogeneic stem Cell transplantation without the use of blood products.
- Strength training following hematopoietic stem Cell transplantation.
- Integrative tumor board: Recurrent Lymphoma.
- Toxicity and therapeutic efficacy of high-dose interleukin 2. In vivo infusion of antibody to NK-1.1 attenuates toxicity without compromising efficacy against murine l...
- T-Cell immunity to the joining region of p210BCR-ABL protein.
- Antigen-driven T cell clones can proliferate in vivo, eradicate disseminated Leukemia, and provide specific immunologic memory.
- Phase I evaluation of humanized OKT3: toxicity and immunomodulatory effects of hOKT3gamma4.
- T-Cell immunity to oncogenic proteins including mutated ras and chimeric bcr-abl.
- Induction of T Cells specific for the mutated segment of oncogenic P21ras protein by immunization in vivo with the oncogenic protein.
- Lysis of ras oncogene-transformed Cells by specific cytotoxic T lymphocytes elicited by primary in vitro immunization with mutated ras peptide.
- CD4+ T-cell immunity to mutated ras protein in pancreatic and colon Cancer patients.
- A phase I trial of interleukin 3 (IL-3) pre-bone marrow harvest with granulocyte-macrophage colony-stimulating factor (GM-CSF) post-stem Cell infusion in patients with...
- Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies.
- Regimen-related toxicity after fludarabine-melphalan conditioning: a prospective study of 31 patients with hematologic malignancies.
- Reliability of a pretransplant i.v. BU test dose performed 2 weeks before myeloablative FluBu conditioning regimen.
- Fludarabine/i.v. BU conditioning regimen: myeloablative, reduced intensity or both?
- Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem Cell transplant.
- Fludarabine-based conditioning for allogeneic transplantation in adults with sickle Cell disease.
- Granulocyte colony-stimulating factor-based stem Cell mobilization in patients with sickle Cell disease.
- Prolonged responses after autologous stem Cell transplantation in African-American patients with multiple myeloma.
- Phase II study of autologous transplantation with interleukin-2-incubated peripheral blood stem Cells and posttransplantation interleukin-2 in relapsed or refractory n...
- Pilot trial of interleukin-2 with granulocyte colony-stimulating factor for the mobilization of progenitor cells in advanced breast Cancer patients undergoing high-dos...
- Comparable kinetics of myeloablation between fludarabine/full-dose busulfan and fludarabine/melphalan conditioning regimens in allogeneic peripheral blood stem Cell tr...
- Low incidence of CMV viremia and disease after allogeneic peripheral blood stem Cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir.
- Allogeneic blood Cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia.
- Changes in telomerase activity and telomere length during human T lymphocyte senescence.
- Induction of human cytotoxic T lymphocytes specific for proState-specific antigen.
- Induction of Tc2 cells with specificity for prostate-specific antigen from patients with hormone-refractory prostate Cancer.
- Efficient transfer of PSA and PSMA cDNAs into DCs generates antibody and T Cell antitumor responses in vivo.
- Induction of specific T cell immunity in patients with prostate Cancer by vaccination with PSA146-154 peptide.
- Long-term follow-up of HLA-A2+ patients with high-risk, hormone-sensitive prostate Cancer vaccinated with the prostate specific antigen peptide homologue (PSA146-154).
Schools
Univ Of Pittsburgh Sch Of Med
University Of Pittsburgh Med Center
University Wa Med Center
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
University of Pittsburgh School of Medicine
Hospital
-
University of Illinois Hospital & Health Sciences System -
MacNeal Hospital -
Jesse Brown Veterans Affairs Medical Center
Helpful Reviews
Similar Doctors
|
|
Dr. Susan H. McDunn, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stanley J. Borowicz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Divyesh G. Mehta, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shuo Ma, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Javed Imam, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hongtao Liu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Irum H. Khan, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Marisa Hill, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sarah T. Lincoln, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Frederick A. Smith, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Susan M. Sharpe, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Andrea Karoff, LCSW |